Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO trial of ART plus dual long-acting HIV broadly neutralizing antibodies versus ART plus placebo during analytical treatment interruption
2024-514564-13-00Phase 2Authorised
- Sponsor
- Imperial College London
- Start
- Jan 2025
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Imperial College London. Primary endpoint: Time to viral rebound within 20 weeks after initial analytical treatment interruption. Planned start Jan 2025; status: authorised.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-514564-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514564-13-00.